{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T17:52:00Z","timestamp":1775929920814,"version":"3.50.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/wnf.0b013e3181342f32","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T07:12:50Z","timestamp":1211958770000},"page":"141-150","source":"Crossref","is-referenced-by-count":151,"title":["A Pilot Clinical Trial of Creatine and Minocycline in Early Parkinson Disease"],"prefix":"10.1097","volume":"31","member":"276","reference":[{"key":"R1-3-20210203","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jama.291.3.358","article-title":"Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions.","volume":"291","author":"Schapira","year":"2004","journal-title":"JAMA"},{"key":"R2-3-20210203","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/mds.20609","article-title":"Burden of illness in Parkinson's disease.","volume":"20","author":"Huse","year":"2005","journal-title":"Mov Disord"},{"key":"R3-3-20210203","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/mds.20727","article-title":"Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.","volume":"21","author":"Noyes","year":"2006","journal-title":"Mov Disord"},{"key":"R4-3-20210203","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1212\/01.wnl.0000201252.57661.e1","article-title":"A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease.","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"R5-3-20210203","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1212\/01.wnl.0000201251.33253.fb","article-title":"Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.","volume":"66","author":"Tilley","year":"2006","journal-title":"Neurology"},{"key":"R6-3-20210203","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/01.wnl.0000250355.28474.8e","article-title":"A randomized, double blind, futility clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson's disease.","volume":"68","year":"2007","journal-title":"Neurology"},{"key":"R7-3-20210203","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","article-title":"Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.","volume":"60","author":"Ravina","year":"2003","journal-title":"Neurology"},{"key":"R8-3-20210203","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.1028","article-title":"Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders.","volume":"49","author":"Tarnopolsky","year":"2001","journal-title":"Ann Neurol"},{"key":"R9-3-20210203","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1592\/phco.26.4.515","article-title":"Minocycline for short-term neuroprotection.","volume":"26","author":"Elewa","year":"2006","journal-title":"Pharmacotherapy"},{"key":"R10-3-20210203","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1006\/exnr.1999.7049","article-title":"Creatine and cyclocreatine attenuate MPTP neurotoxicity.","volume":"157","author":"Matthews","year":"1999","journal-title":"Exp Neurol"},{"key":"R11-3-20210203","doi-asserted-by":"crossref","first-page":"14669","DOI":"10.1073\/pnas.251341998","article-title":"Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.","volume":"98","author":"Du","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R12-3-20210203","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1523\/JNEUROSCI.22-05-01763.2002","article-title":"Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.","volume":"22","author":"Wu","year":"2002","journal-title":"J Neurosci"},{"key":"R13-3-20210203","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/jnr.10709","article-title":"Minocycline enhances MPTP toxicity to dopaminergic neurons.","volume":"74","author":"Yang","year":"2003","journal-title":"J Neurosci Res"},{"key":"R14-3-20210203","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1111\/j.0953-816X.2004.03372.x","article-title":"Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease.","volume":"19","author":"Diguet","year":"2004","journal-title":"Eur J Neurosci"},{"key":"R15-3-20210203","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/ana.20361","article-title":"A responsive outcome for Parkinson's disease neuroprotection futility studies.","volume":"57","author":"Elm","year":"2005","journal-title":"Ann Neurol"},{"key":"R16-3-20210203","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.toxlet.2004.01.013","article-title":"Creatine: are the benefits worth the risk?","volume":"150","author":"Brudnak","year":"2004","journal-title":"Toxicol Lett"},{"key":"R17-3-20210203","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1525-1470.1999.00106.x","article-title":"Complications of minocycline therapy for acne vulgaris: case reports and review of the literature.","volume":"16","author":"Somech","year":"1999","journal-title":"Pediatr Dermatol"},{"key":"R18-3-20210203","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1212\/01.WNL.0000125321.92112.7E","article-title":"Placebo-controlled phase I\/II studies of minocycline in amyotrophic lateral sclerosis.","volume":"62","author":"Gordon","year":"2004","journal-title":"Neurology"},{"key":"R19-3-20210203","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-2004-817917","article-title":"Few adverse effects of long-term creatine supplementation in a placebo-controlled trial.","volume":"26","author":"Groeneveld","year":"2005","journal-title":"Int J Sports Med"},{"key":"R20-3-20210203","first-page":"1044","article-title":"Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.","volume":"61","author":"Holloway","year":"2004","journal-title":"Arch Neurol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200805000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T01:51:37Z","timestamp":1618278697000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200805000-00003"}},"subtitle":["18-Month Results"],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e3181342f32","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}